Personalis, Inc. to Provide Tumor Immunogenomic Profiling to the Parker Institute for Immunotherapy Biomarker Discovery in Clinical Trial Participants

May 22, 2019 Off By BusinessWire

MENLO PARK, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/parkerici?src=hash" target="_blank"gt;#parkericilt;/agt;–Personalis, Inc., a leader in advanced genomics for cancer, today
announced that the Parker
Institute for Cancer Immunotherapy
will utilize Personalis’ cancer
immunogenomics platform, ImmunoID
NeXT
™, for the investigation of biomarkers of response to
immunotherapies in clinical trial participants. The trials include
melanoma, pancreatic, and all-comer solid tumor patients treated with
checkpoint inhibitors, either as monotherapy or in combination with
other cancer therapeutics. This project builds on Personalis’ existing
relationship with the Parker Institute as a contributing industry member
of the TESLA
Consortium
, which focuses on improving neoantigen prediction
algorithms.

Unlike traditional biomarker interrogation approaches that require
several individual assays, which may be costly and time-consuming, and
which may exhaust limited tumor tissue sample, ImmunoID NeXT™
consolidates multiple biomarker assays into one, meaning researchers no
longer need to make the difficult choice regarding which biomarkers to
analyze. The platform represents an end-to-end solution for immuno and
precision oncology biomarker discovery applications, simultaneously
enabling the analysis of: tumor mutations, neoantigens, immune
repertoire clonality, tumor escape mechanisms (including HLA-related
somatic mutations and genotyping), tumor mutational burden (TMB),
microsatellite instability (MSI), oncoviruses, and more.

“Personalis’ platform could help us better understand which patients
will respond or not respond to immunotherapy and why,” said Theresa
LaVallee, PhD, VP Translational Medicine and Regulatory Affairs at the
Parker Institute.

“We’re excited to work with the Parker Institute on this important new
project,” said Dr. Richard Chen, MD, Personalis’ Chief Scientific
Officer. “Both organizations are focused on improving outcomes for
cancer patients, and we believe that ImmunoID NeXT™ is the catalyst that
our partners and customers can leverage to discover more effective
biomarkers of response to immunotherapies.”

About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the
development of next-generation therapies by providing more comprehensive
molecular data about each patient’s cancer and immune response. The
company’s NeXT™
Platform
is designed to adapt to the complex and evolving
understanding of cancer, providing its biopharmaceutical customers with
information on all of the approximately 20,000 human genes, together
with the immune system, from a single tissue sample. The Personalis Clinical
Laboratory
is GxP aligned as well as CLIA’88-certified and
CAP-accredited. For more information, please visit www.personalis.com
and follow Personalis on Twitter (@PersonalisInc).

Contacts

Media Contact for Personalis:
Jennifer Havlek
[email protected]
www.personalis.com
650-752-1300